Tepotinib-induced interstitial lung disease in a patient with adenosquamous lung carcinoma.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: possible pre-existing ILD
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
This case underscores the potential of early onset ILD with tepotinib, especially in patients with possible pre-existing ILD. Close monitoring and early intervention are essential, and further studies are needed to clarify the risk factors for MET-TKI-induced ILD.
We report a case of drug-induced lung injury in an 88-year-old man with non-small cell lung cancer harboring an MET exon 14 skipping mutation.
APA
Imakura T, Kakiuchi S, et al. (2026). Tepotinib-induced interstitial lung disease in a patient with adenosquamous lung carcinoma.. Respiratory medicine case reports, 59, 102355. https://doi.org/10.1016/j.rmcr.2025.102355
MLA
Imakura T, et al.. "Tepotinib-induced interstitial lung disease in a patient with adenosquamous lung carcinoma.." Respiratory medicine case reports, vol. 59, 2026, pp. 102355.
PMID
41624949 ↗
Abstract 한글 요약
We report a case of drug-induced lung injury in an 88-year-old man with non-small cell lung cancer harboring an MET exon 14 skipping mutation. The patient developed dyspnea and new ground-glass opacities shortly after the initiation of tepotinib, an oral MET-tyrosine kinase inhibitor (MET-TKI). Clinical findings and laboratory data supported the diagnosis of tepotinib-induced interstitial lung disease (ILD). High-dose corticosteroid therapy led to improvement, and the patient was discharged. This case underscores the potential of early onset ILD with tepotinib, especially in patients with possible pre-existing ILD. Close monitoring and early intervention are essential, and further studies are needed to clarify the risk factors for MET-TKI-induced ILD.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Whole-body MRI for staging and follow-up of primary musculoskeletal tumours: a systematic review.
- Reforming the delivery of smoking cessation: a distributional cost-effectiveness analysis of providing smoking cessation as part of targeted lung cancer screening.
- A herbal formulation inhibits growth and survival of lung cancer cells through DNA damage and apoptosis - in vitro and in vivo studies.
- Negative trial but positive lesson: reframing immunotherapy resistance from one-size-fits-all to precision strategies.
- Lung Cancer Screening in Adults: State-of-the-Art and Policy Mapping (2025).
- Retrospective dosimetric evaluation of the collapsed cone, AAA, and Acuros XB algorithms for lung cancer Halcyon VMAT plans.